UAE Biosimilar Registration: Requirements and Pathways
The UAE has built a detailed and increasingly mature framework for the registration and market authorisation of biologic and biosimilar products.
The UAE has built a detailed and increasingly mature framework for the registration and market authorisation of biologic and biosimilar products.
Reviewed by Mohamed Noureldin, Founder, Managing Partner & Senior Legal Consultant
UAE Biosimilar Registration: Requirements, Pathways and Compliance
Related Services: Explore our trademark registration services in the UAE and AML compliance services for practical legal support in this area.
Introduction to Biosimilar Registration in the UAE
The United Arab Emirates (UAE) has built a detailed and increasingly mature framework for the registration and market authorisation of biologic and biosimilar products. Biosimilar registration in the UAE has become a priority for federal and local health authorities as the patent cliff erodes the market exclusivity of many high-revenue biologic medicines.
The framework aims to balance three objectives: promoting cost competition, expanding patient access to advanced therapies, and upholding strict standards of safety, quality and efficacy. Registration is a rigorous undertaking. Manufacturers must provide a comprehensive data dossier that demonstrates biosimilarity to a reference biologic product.
This article analyses the legal and regulatory requirements that govern the biosimilar registration process in the UAE. It outlines the key procedures, the strategic implications and the operational structure of this area of pharmaceutical law. Understanding this environment is essential for any business seeking to overcome market barriers and register a product successfully.
Legal Framework and Regulatory Overview
Pharmaceutical regulation in the UAE is a multi-layered system administered by both federal and Emirate-level authorities. The primary federal body is the Ministry of Health and Prevention (MOHAP), which holds the mandate for registering and regulating all medical and pharmaceutical products across the country.
The health authorities in Dubai and Abu Dhabi, the Dubai Health Authority (DHA) and the Department of Health – Abu Dhabi (DOH), maintain significant autonomy in regulating healthcare services and procurement within their own jurisdictions. Manufacturers must therefore deal with differences between regulators.
The UAE's biosimilar registration framework rests on the principle of comparability. A biosimilar cannot be approved as a standalone product. Its entire regulatory submission is designed to prove, through extensive scientific evidence, that it is highly similar to an already approved reference biologic.
The UAE largely aligns its standards with those of globally recognised stringent regulatory authorities, such as the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA). Products already approved by these bodies often face a more streamlined, though still rigorous, review in the UAE.
The legal basis for this is grounded in federal laws governing pharmaceutical products. These laws empower MOHAP to set the specific data requirements for different drug categories, including the advanced and complex category of biologics and biosimilars. As a result, the UAE promotes market competition through biosimilar registration without compromising patient safety or product quality. For applicants, the process is demanding but predictable.
Key Requirements and Procedures for Biosimilar Registration in the UAE
Securing biosimilar registration in the UAE follows a clearly defined, multi-stage procedure. It is designed to test the applicant's claims of biosimilarity rigorously. Moving from dossier submission to market authorisation requires a solid grasp of the procedural details and a proactive approach to dealing with the regulator.
Pre-Submission and Dossier Preparation
Before a formal submission, manufacturers are encouraged to hold preliminary discussions with MOHAP. These interactions are informal, but they are an important part of a successful registration strategy. They help applicants clarify specific data requirements, understand the regulator's expectations and identify potential challenges early.
The dossier must be prepared with precision and must follow the Common Technical Document (CTD) format strictly. It is a comprehensive compilation of administrative, quality, non-clinical and clinical data.
A critical element is the choice of reference biologic. The reference product must be a biologic that is already registered and marketed in the UAE. If the reference product used in global clinical trials was sourced from outside the UAE (for example, an EMA- or FDA-approved product), the applicant must provide a robust justification and bridging data showing its comparability to the UAE-registered reference product. This requirement is designed to address any discrepancies arising from different manufacturing standards or product formulations.
Clinical and Non-Clinical Data Requirements
The comparability exercise is the cornerstone of a biosimilar application. The applicant must carry out a comprehensive set of analytical studies to show that the product is highly similar to the reference biologic in its structural and functional characteristics. This includes extensive characterisation studies that compare critical quality attributes.
After the analytical studies, the dossier must include non-clinical and clinical data. The non-clinical component typically involves in vitro studies and, if necessary, in vivo animal studies to assess toxicity.
The clinical data package is the most closely scrutinised part of the submission. It must include pharmacokinetic (PK) and pharmacodynamic (PD) studies to demonstrate comparable bioavailability and biological effect. In addition, at least one confirmatory clinical efficacy and safety trial is typically required. This trial is designed to confirm that there are no clinically meaningful differences between the biosimilar and the reference biologic. Trial design attracts significant scrutiny, and applicants must be prepared to defend their methodological choices.
Post-Approval and Pharmacovigilance
Market authorisation does not end the regulatory process. The UAE has a robust pharmacovigilance system, and all marketing authorisation holders are required to actively monitor the safety of their products once they are on the market. For biosimilars, this requirement is particularly strict.
Manufacturers must establish and maintain a comprehensive Risk Management Plan (RMP). The RMP is a living document that sets out the known and potential risks of the product and the measures that will be taken to minimise those risks and monitor the outcomes. It includes ongoing safety surveillance, periodic safety update reports (PSURs) and, in some cases, post-authorisation safety studies (PASS).
These post-approval obligations are an important safeguard. They protect the long-term safety and efficacy of biosimilars, maintain public confidence in these products, and allow emerging risks to be identified and managed so that wider access to biologics is not compromised.
| Pathway | Description | Key Considerations |
|---|---|---|
| Standard Pathway | The default and most rigorous route, requiring a complete comparability exercise against a UAE-approved reference biologic. | The data requirements are extensive, with a full set of quality, non-clinical and clinical studies, including a confirmatory efficacy and safety trial. The process is demanding from start to finish. |
| Facilitated Pathway (Reference Authority) | Designed for biosimilars already approved by a stringent reference authority such as the EMA or FDA. | A full local clinical trial may be waived, but the applicant must provide comprehensive bridging data to justify the relevance of the foreign data to the UAE context. The regulatory review remains robust. |
| Parallel Review | An exceptional pathway for products of significant public health interest that are under review by a reference authority at the same time. | This route involves close collaboration between MOHAP and the other regulatory body. It is complex and reserved for high-priority medicines where market access needs to be expedited. |
Strategic Implications
The UAE's biosimilar registration framework has significant implications for every stakeholder in the healthcare sector. For pharmaceutical manufacturers, it is both a major opportunity and a serious challenge. The opportunity lies in a lucrative market for off-patent biologics. However, the rigour of the registration process demands substantial investment in high-quality data and regulatory expertise.
Manufacturers need a well-planned regulatory strategy that anticipates and addresses potential objections from the health authorities. This means careful dossier preparation, proactive engagement with regulators and a sound understanding of local market dynamics. The framework's dual federal and Emirate-level components add a further layer of complexity, so a successful strategy must address the requirements of all relevant authorities in a coordinated way.
For payors, both public and private, biosimilars are a powerful tool for cost containment. Competition in the biologics market can lead to significant price reductions, freeing up resources for other areas of healthcare. Realising these savings, however, requires effective uptake policies. These may include physician education, prescribing incentives and clear guidelines for switching patients from reference biologics to biosimilars. The information gap between manufacturers and payors can be a significant barrier, and payors must build the analytical capability to assess the true value of different products.
For patients and healthcare providers, the main implication is wider access to life-changing biologic therapies. The cost of originator biologics can be a significant barrier, and more affordable biosimilars can expand treatment options and improve health outcomes. The UAE's robust pharmacovigilance system provides important assurance of safety and quality, building confidence among clinicians and patients in the use of biosimilars.
Conclusion
The UAE has put in place a comprehensive and sound legal framework for the registration of biosimilar products. The framework is deliberately rigorous, designed to validate the safety, quality and efficacy of biosimilars before granting market access. It is characterised by alignment with stringent international standards, multi-layered regulatory oversight and robust post-market pharmacovigilance requirements.
For manufacturers, working within this framework requires significant resources and a solid understanding of pharmaceutical law. Successful biosimilar registration in the UAE is not only a matter of scientific demonstration but also a test of regulatory strategy and operational discipline. The emphasis on a full comparability exercise and detailed data requirements is designed to manage risk and ensure that only high-quality, reliable biosimilars reach the market.
Ultimately, the UAE's biosimilar framework balances innovation, patient access and healthcare sustainability. By creating a clear but challenging pathway for biosimilar entry, the UAE is fostering a competitive market that can lower the cost of biologic therapies while upholding the highest standards of public health. As the biologics market evolves, this regulatory framework will remain a cornerstone of the country's healthcare strategy.
Businesses seeking to enter this market must be prepared for a demanding process and should seek expert advice on the system's complexities. For guidance on this and other matters of corporate and commercial law, it is important to work with a legal team that has deep sector experience. Our team of legal experts at Nour Attorneys can provide the strategic advice needed to meet these challenges. We encourage you to contact us for a consultation on building a successful regulatory strategy for your products, including managing the interface with intellectual property rights.
Additional Resources
Explore more of our insights on related topics: